Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM2 | Q14416 | 1/20 | 0.46 |
| ▸ | CCR9 | P51686 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 4/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.41 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.41 |
| ▸ | MTNR1A | P48039 | 6/20 | 0.40 |
| ▸ | MTNR1B | P49286 | 6/20 | 0.40 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.39 |
| ▸ | CA2 | P00918 | 1/20 | 0.39 |
| ▸ | CCR2 | P41597 | 1/20 | 0.37 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.36 |
| ▸ | HTR2A | P28223 | 1/20 | 0.36 |
| ▸ | HTR2C | P28335 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4305280 | 0.85 | PDE5A (0.43) | GRM2CCR9MAPTSMN1; SMN2NPSR1 | |
| SCHEMBL4308603 | 0.82 | GRM2 (0.44) | GRM2CCR9MAPTSMN1; SMN2NPSR1 | |
| SCHEMBL13924694 | 0.82 | CCR9 (0.44) | GRM2CCR9MAPTSMN1; SMN2NPSR1 | |
| SCHEMBL4310993 | 0.81 | LYN (0.49) | GRM2CCR9MAPTSMN1; SMN2NPSR1 | |
| SCHEMBL4308707 | 0.81 | CCR9 (0.54) | CCR9MAPTCCR2 | |
| SCHEMBL4315297 | 0.80 | CCR9 (0.47) | CCR9MAPTMTNR1AMTNR1BCCR2 | |
| SCHEMBL4311962 | 0.79 | MAPT (0.41) | CCR9MAPTRXFP1MTNR1AMTNR1B | |
| SCHEMBL4308755 | 0.78 | GRM2 (0.40) | GRM2CCR9MAPTSMN1; SMN2NPSR1 | |
| SCHEMBL4317662 | 0.78 | CCR9 (0.40) | GRM2CCR9MAPTMTNR1AMTNR1B | |
| SCHEMBL4318320 | 0.78 | MAPT (0.40) | CCR9MAPTMTNR1AMTNR1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090062280-A1 | Ophthalmic Compositions for Treating Ocular Hypertension | MERCK SHARP & DOHME CORP. | 2009-03-05 | — | — | US | disclosed |
| US-20090062280-A1 | Ophthalmic Compositions for Treating Ocular Hypertension | MERCK SHARP & DOHME CORP. | 2009-03-05 | — | — | US | disclosed |
| US-20090062280-A1 | Ophthalmic Compositions for Treating Ocular Hypertension | MERCK SHARP & DOHME CORP. | 2009-03-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090062280-A1 | Ophthalmic Compositions for Treating Ocular Hypertension | KCNN3, KCNN1, KCNN2 | GRM2 687/4885CCR9 4698/4885MAPT 498/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.